ASTECPesticides & Agrochemicals
Astec LifeSciences Ltd — Profit & Loss Statement
₹540.60
-7.01%
Astec LifeSciences Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.12 Cr | -0.03 Cr | -0.11 Cr | 0.52 Cr | — |
| Tax Rate For Calcs | 0.04 | 0.24 | 0.27 | 0.26 | — |
| Normalized EBITDA | -63.64 Cr | -0.53 Cr | 89.17 Cr | 162.16 Cr | — |
| Total Unusual Items | 2.64 Cr | -0.11 Cr | -0.41 Cr | 2.01 Cr | — |
| Total Unusual Items Excluding Goodwill | 2.64 Cr | -0.11 Cr | -0.41 Cr | 2.01 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | -134.75 Cr | -46.93 Cr | 25.56 Cr | 89.86 Cr | — |
| Reconciled Depreciation | 43.71 Cr | 36.25 Cr | 33.65 Cr | 34.36 Cr | — |
| Reconciled Cost Of Revenue | 302.71 Cr | 323.32 Cr | 405.43 Cr | 390.84 Cr | — |
| EBITDA | -61.00 Cr | -0.64 Cr | 88.76 Cr | 164.18 Cr | — |
| EBIT | -104.71 Cr | -36.89 Cr | 55.11 Cr | 129.82 Cr | — |
| Net Interest Income | -35.89 Cr | -25.07 Cr | -16.67 Cr | -8.79 Cr | — |
| Interest Expense | 36.28 Cr | 24.86 Cr | 20.16 Cr | 8.69 Cr | — |
| Interest Income | 0.80 Cr | 0.15 Cr | 4.05 Cr | 0.26 Cr | — |
| Normalized Income | -137.28 Cr | -46.84 Cr | 25.86 Cr | 88.36 Cr | — |
| Net Income From Continuing And Discontinued Operation | -134.75 Cr | -46.93 Cr | 25.56 Cr | 89.86 Cr | — |
| Total Expenses | 491.22 Cr | 499.77 Cr | 584.64 Cr | 556.23 Cr | — |
| Rent Expense Supplemental | 1.06 Cr | 1.16 Cr | 1.07 Cr | 1.02 Cr | — |
| Diluted Average Shares | 1.98 Cr | 1.98 Cr | 1.98 Cr | 1.97 Cr | — |
| Basic Average Shares | 1.98 Cr | 1.98 Cr | 1.98 Cr | 1.97 Cr | — |
| Diluted EPS | -68.19 | -23.75 | 12.94 | 45.50 | — |
| Basic EPS | -68.19 | -23.75 | 12.94 | 45.52 | — |
| Diluted NI Availto Com Stockholders | -134.75 Cr | -46.93 Cr | 25.56 Cr | 89.86 Cr | — |
| Net Income Common Stockholders | -134.75 Cr | -46.93 Cr | 25.56 Cr | 89.86 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | -134.75 Cr | -46.93 Cr | 25.56 Cr | 89.86 Cr | — |
| Minority Interests | -0.04 Cr | -0.04 Cr | -0.03 Cr | -0.02 Cr | — |
| Net Income Including Noncontrolling Interests | -134.71 Cr | -46.89 Cr | 25.59 Cr | 89.88 Cr | — |
| Net Income Discontinuous Operations | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income Continuous Operations | -134.71 Cr | -46.89 Cr | 25.59 Cr | 89.88 Cr | — |
| Tax Provision | -6.28 Cr | -14.86 Cr | 9.35 Cr | 31.24 Cr | — |
| Pretax Income | -140.99 Cr | -61.75 Cr | 34.95 Cr | 121.13 Cr | — |
| Other Non Operating Income Expenses | 0.60 Cr | 0.06 Cr | 0.10 Cr | 0.33 Cr | — |
| Special Income Charges | 2.64 Cr | -0.11 Cr | -0.41 Cr | 2.01 Cr | — |
| Other Special Charges | -2.64 Cr | 0.11 Cr | 0.41 Cr | -2.01 Cr | — |
| Net Non Operating Interest Income Expense | -35.89 Cr | -25.07 Cr | -16.67 Cr | -8.79 Cr | — |
| Total Other Finance Cost | 0.42 Cr | 0.37 Cr | 0.56 Cr | 0.36 Cr | — |
| Interest Expense Non Operating | 36.28 Cr | 24.86 Cr | 20.16 Cr | 8.69 Cr | — |
| Interest Income Non Operating | 0.80 Cr | 0.15 Cr | 4.05 Cr | 0.26 Cr | — |
| Operating Income | -109.92 Cr | -41.59 Cr | 43.53 Cr | 120.33 Cr | — |
| Operating Expense | 188.51 Cr | 176.46 Cr | 179.21 Cr | 165.40 Cr | — |
| Other Operating Expenses | 67.79 Cr | 64.91 Cr | 70.99 Cr | 59.84 Cr | — |
| Depreciation And Amortization In Income Statement | 43.71 Cr | 36.25 Cr | 33.65 Cr | 34.36 Cr | — |
| Amortization | -0.41 Cr | -0.31 Cr | 0.38 Cr | 0.70 Cr | — |
| Depreciation Income Statement | 44.12 Cr | 36.56 Cr | 33.28 Cr | 33.65 Cr | — |
| Research And Development | 2.14 Cr | 2.70 Cr | 1.49 Cr | 0.91 Cr | — |
| Selling General And Administration | 12.37 Cr | 9.76 Cr | 19.77 Cr | 18.98 Cr | — |
| Selling And Marketing Expense | 5.15 Cr | 2.63 Cr | 7.51 Cr | 10.83 Cr | — |
| General And Administrative Expense | 7.23 Cr | 7.14 Cr | 12.26 Cr | 8.14 Cr | — |
| Rent And Landing Fees | 1.06 Cr | 1.16 Cr | 1.07 Cr | 1.02 Cr | — |
| Gross Profit | 78.59 Cr | 134.86 Cr | 222.73 Cr | 285.73 Cr | — |
| Cost Of Revenue | 302.71 Cr | 323.32 Cr | 405.43 Cr | 390.84 Cr | — |
| Total Revenue | 381.30 Cr | 458.18 Cr | 628.17 Cr | 676.57 Cr | — |
| Operating Revenue | 381.30 Cr | 458.18 Cr | 628.17 Cr | 676.57 Cr | — |
| Write Off | — | — | — | 0.25 Cr | 0.11 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Astec LifeSciences Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.